We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Accelrys Announces Purchase of Cloud-based HEOS from SCYNEXIS
Product News

Accelrys Announces Purchase of Cloud-based HEOS from SCYNEXIS

Accelrys Announces Purchase of Cloud-based HEOS from SCYNEXIS
Product News

Accelrys Announces Purchase of Cloud-based HEOS from SCYNEXIS

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Accelrys Announces Purchase of Cloud-based HEOS from SCYNEXIS"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Accelrys, Inc. has announced that it has purchased the Web-based Hit Explorer Operating System (HEOS) from SCYNEXIS, Inc. The HEOS purchase is the final phase of a strategic agreement that began in 2011, which enabled Accelrys to market and sell HEOS as a key offering within Accelrys' market-leading Cheminformatics Suite of software applications.

HEOS enables more efficient and streamlined drug discovery collaborations, particularly for organizations leveraging academic departments, research institutes and contract research organizations (CROs) in externalized R&D projects.

Enabled by Accelrys applications, HEOS is a proven Software-as-a-Service (SaaS) workspace that accelerates and streamlines collaborative drug discovery by providing secure, real-time access to chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information in the Cloud with minimal IT overhead and effort.

"HEOS supports an important new operating model for collaborating organizations that require secure, flexible information management and collaboration with global reach," said Accelrys President and Chief Executive Officer Max Carnecchia.

Carnecchia continued, "As many of our customers move to multi-site, multi-collaborator projects to accelerate innovation and reduce costs, we look forward to broadening the applicability and reach of HEOS as a secure, easy-to-use, Cloud-based information management workspace for the wider scientific community."

HEOS has already securely captured hundreds of thousands of compounds and millions of assay test results in a broad range of global pharmaceutical and biotechnology programs ranging from early discovery to preclinical projects.

A worldwide network of organizations is currently using the system to capture, consolidate and harmonize data used in the study of neglected diseases.

Accelrys' purchase of the HEOS SaaS-based system includes software and supporting personnel.

To learn more about HEOS, watch the on-demand introductory webinar "Introducing HEOS - A Cloud-based Collaborative Drug Discovery Workspace."